• CanSinoBIO’s CEO Xuefeng Yu attended the World Economic Forum’s Sustainable Development Impact Meetings in New York on Sept. 21-24.
• Yu highlighted AI-driven disease surveillance and data analytics as levers to speed vaccine discovery, R&D efficiency, clinical development.
• First-half revenue totaled RMB 550 million, up 43.8% year on year; overseas revenue reached RMB 152 million.
• Menhycia, a quadrivalent meningococcal conjugate vaccine, won marketing authorization in Indonesia and Argentina.
• Pipeline updates cited a Phase I trial clearance in Indonesia for an inhaled TB vaccine; VLP-Polio Phase II results were positive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief on September 26, 2026, and is solely responsible for the information contained therein.